Prior to the 112th Congress adjourning, the House and Senate voted to approve H.R. 1845, which is designed to increase access to intravenous immune globin (IVIG) and reform Medicare Secondary Payer (MSP) program rules, and President Obama signed the bill into law on January 10, 2013. First, H.R. 1845 requires the HHS Secretary to implement a demonstration project to evaluate the benefits of providing Medicare Part B payment for items and services needed for the in-home administration of IVIG for the treatment of primary immune deficiency diseases. Second, H.R. 1845 makes a series of revisions to MSP rules that formerly were included in H.R. 1063, the Strengthening Medicare and Repaying Taxpayers (SMART) Act. Among other things, the law requires Medicare to provide settling parties with conditional information about the total costs of medical bills when the parties announce a settlement is near; the intention of this provision is to prevent settlements from collapsing because parties cannot determine how much they owe Medicare. The law also directs the HHS Secretary to promulgate regulations establishing a right of appeal for final payment amounts; prohibits the Secretary from seeking payment of claims that are less that the cost of recouping such payment (the applicable threshold will be determined by the Secretary); makes discretionary the current mandatory civil monetary penalty for an applicable plan’s noncompliance; requires the Secretary to promulgate regulations establishing safe harbors from the MSP reporting requirements; and establishes a 3-year statute of limitations for the MSP program.